Cosciens Biopharma Inc.TSX: CSCI

Aeterna Zentaris' Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint in Men with Heavily Pretreated Castration and Taxane Resistant Prostate Cancer

Sep 28, 2015 at 3:00 PM UTC · Issued by Cosciens Biopharma Inc. via CNW

Paul Burroughs, Director of Communications, (418) 652-8525 ext. 406, pburroughs@aezsinc.comCopyright CNW Group 2015